With the support of the VIB, the SBRC has co-founded several startup companies, based on breakthrough research.

• AbLynx is focused on the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases including inflammation, haematology, oncology and pulmonary disease.
• AgroSavfe employs its proprietary Agrobody™ technology platform to develop superior crop protection products, based on active ingredients with proven efficacy, in combination with Agrobodies™ as formulation agents.
• Confo Therapeutics uses single domain antibodies to stabilize dynamic proteins, in order to improve drug discovery processes.